PPT-Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive

Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe  Pathologie des Cellules Lymphoïdes  UMR 5239 CNRS UCB ENS HCL The Lymphoma Study Association One question lot of possibilities.  . Michael E. . Schuckers. * . St. Lawrence . University. Statistical . Sports . Consulting. Canton, NY. . schuckers@stlawu.edu.  .  . *Thanks to Chris Smith SLU ‘09, Chris Wells, Steve Bowman, Brian . Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Koç University Medical School Istanbul/Turkey. Aegean Hematology Oncology Symposium 17-20 Sep 2015. Is . R-CHOP . the standart treatment . for . high-risk DLBCL. Objectives. Introduction and risk assesment of DLBCL. Andy Chen, MD PhD. Center for Hematologic Malignancies. Knight Cancer Institute. Oregon Health & Science University. January 2012. Disclosures. Clinical trials: Seattle Genetics, Otsuka, Genentech. USE OF ANAESTHETIC AGENTS. R MAHARAJ. LECTURE OUTLINE. CURRENT CONCEPTS ON DEFINITION AND MANAGEMENT. DEFINITIONS. ANEASTHETIC AGENTS USED. THE IDEAL ANAESTHETIC AGENT. SUMMARY. CURRENT THINKING??. More aggressive and early treatment of seizures. Utku Uysal, M.D. M.S.. Seizure: . “a . transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The term transient is used as demarcated in time, with a clear start and finish.” . Program Goals. DLBCL Subtypes . 2008 WHO Classification. Other DLBCL Variants. Dissecting DLBCL into Molecularly and Clinically Distinct Subgroups by Gene Expression Profiling. Outcomes Based on DLBCL Subtype Using Gene Expression Profiling. 1inaccessibility for hydrolysis or/and chemical resistanceS Decremps E Paul F Vedrenne JA Cacho Rivero and X LefebvreUniversit de ToulouseINSA UPS INPLISBP 135 Avenue de Rangueil F-31077 Toulouse Fra B-Cell . Lymphoma (DLBCL) Patients, . 1983 . – 2014. results from . analysis of US SEER data. Ron . Dewar, . Registry and . Analytics,. Nova Scotia Health Authority (Canada). Nadia . Howlader. , Angela . contributes inferior outcome in DLBCL . . R4 . 簡聖軒. 指導老師. : . 高志平大夫. Outline . Maturation of B lymphocyte . DLBCL classification . Souto GR, Pereira TSF, Castro AF, Mesquita RA. Diffuse large B-cell eMail: jced@jced.es Scopus DOI® System oi:10.4317/jced.51127http://dx.doi.org/10.4317/jced.51127IntroductionDiffuse large B-cell (PMAL) Consortium and Associated Trials. 2016. CONFIDENTIAL. The new name for . Leukaemia. & Lymphoma Research. Tackling Diffuse Large B-cell Lymphoma. 2. Clinical Problem. Standard of care, RCHOP, results in cure rates around 75%. Jean Koff, MD, MSc. July 20, 2023. disclosures. Research funding. : . Oncternal. Therapeutics; Viracta Therapeutics; Atara . Biotherapeutics. Consulting fees: . Janssen / . Pharmacyclics. ; . MorphoSys. Diffuse Large B Cell Lymphoma. Foroud. . shahbazi. . Pharm.D. Introduction . Diffuse large B cell lymphoma (DLBCL) is the most common form . of aggressive . NHL accounting for approximately 30%-40% of cases.